Logo image of SNGX

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

NASDAQ:SNGX - US8342236044 - Common Stock

3.38 USD
+0.02 (+0.6%)
Last: 8/22/2025, 8:00:02 PM
3.39 USD
+0.01 (+0.3%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

2

SNGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNGX had negative earnings in the past year.
In the past year SNGX has reported a negative cash flow from operations.
SNGX had negative earnings in each of the past 5 years.
In the past 5 years SNGX always reported negative operating cash flow.
SNGX Yearly Net Income VS EBIT VS OCF VS FCFSNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -123.78%, SNGX is not doing good in the industry: 80.69% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -265.42%, SNGX is doing worse than 69.40% of the companies in the same industry.
Industry RankSector Rank
ROA -123.78%
ROE -265.42%
ROIC N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNGX Yearly ROA, ROE, ROICSNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

SNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNGX Yearly Profit, Operating, Gross MarginsSNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNGX has more shares outstanding
SNGX has more shares outstanding than it did 5 years ago.
SNGX has a better debt/assets ratio than last year.
SNGX Yearly Shares OutstandingSNGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SNGX Yearly Total Debt VS Total AssetsSNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -44.75, we must say that SNGX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -44.75, SNGX is not doing good in the industry: 91.62% of the companies in the same industry are doing better.
SNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.75
ROIC/WACCN/A
WACC10.08%
SNGX Yearly LT Debt VS Equity VS FCFSNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

SNGX has a Current Ratio of 1.85. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.85, SNGX is doing worse than 76.50% of the companies in the same industry.
SNGX has a Quick Ratio of 1.85. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.85, SNGX is doing worse than 75.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.85
SNGX Yearly Current Assets VS Current LiabilitesSNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

SNGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.57%, which is quite impressive.
Looking at the last year, SNGX shows a very negative growth in Revenue. The Revenue has decreased by -85.78% in the last year.
SNGX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.88% yearly.
EPS 1Y (TTM)63.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.4%
Revenue 1Y (TTM)-85.78%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SNGX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.16% on average per year.
Based on estimates for the next years, SNGX will show a small growth in Revenue. The Revenue will grow by 6.88% on average per year.
EPS Next Y53.09%
EPS Next 2Y32.34%
EPS Next 3Y21.16%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SNGX Yearly Revenue VS EstimatesSNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2M 4M 6M 8M 10M
SNGX Yearly EPS VS EstimatesSNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.
Also next year SNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNGX Price Earnings VS Forward Price EarningsSNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNGX Per share dataSNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

SNGX's earnings are expected to grow with 21.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.34%
EPS Next 3Y21.16%

More info and screens

0

5. Dividend

5.1 Amount

SNGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLIGENIX INC

NASDAQ:SNGX (8/22/2025, 8:00:02 PM)

After market: 3.39 +0.01 (+0.3%)

3.38

+0.02 (+0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners4.56%
Inst Owner Change19%
Ins Owners0.02%
Ins Owner Change0%
Market Cap14.50M
Analysts82.86
Price Target22.95 (578.99%)
Short Float %10.4%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.38%
Min EPS beat(2)-55.11%
Max EPS beat(2)-17.65%
EPS beat(4)2
Avg EPS beat(4)-3.82%
Min EPS beat(4)-55.11%
Max EPS beat(4)29.84%
EPS beat(8)5
Avg EPS beat(8)9.76%
EPS beat(12)8
Avg EPS beat(12)-9.16%
EPS beat(16)10
Avg EPS beat(16)-6.52%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)125%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.46%
EPS NY rev (1m)18.55%
EPS NY rev (3m)18.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6304.43
P/FCF N/A
P/OCF N/A
P/B 4.01
P/tB 4.01
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.78%
ROE -265.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.85
Altman-Z -44.75
F-Score3
WACC10.08%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.4%
EPS Next Y53.09%
EPS Next 2Y32.34%
EPS Next 3Y21.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-85.78%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y10.5%
Revenue Next 3Y6.88%
Revenue Next 5YN/A
EBIT growth 1Y-38.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.07%
OCF growth 3YN/A
OCF growth 5YN/A